At the same time, drugmakers have come to rely on the U.S. market for the bulk of their revenue. In 2022, the U.S. accounted ...

We recently published a list of Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key Stocks In this article, ...

Levies on Americans’ daily prescriptions and other medicines could raise costs, spur rationing and lead to shortages of ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White ...

Eli Lilly (LLY) stock in focus as the company projects earnings headwinds from IPR&D charges estimated at $1.57B for Q1 2025.

In this week’s edition of InnovationRx, we look at the impact of Medicaid cuts, a $400 million obesity bet, a study of bias ...